Search for: [Abstract = "rning. An Ewing test battery was used to assess the presence and sophistication of CAN. In the T1DM group treated with CSII cardiovascular autonomic neuropathy was significantly less common than in the classical insulin pen group \(p<0.001\). The retrospective metabolic compensation rate \(HbA1c\) was significantly lower in the CSII\-treated group \(HbA1c 7.44±1.14% vs 8.55±1.67 p=0.049\). Patients diagnosed with CAN had a longer duration of diabetes and co\-occurrence of chronic kidney disease. In addition, in the analyzed population, 87% of patients over 40 years of age had elevated LDL cholesterol values, and more than 70% of patients also had elevated levels of non\-HDL cholesterol. Patients treated with CSII had statistically significantly lower triglyceride levels. The use of modern technologies in the treatment of T1DM helps to achieve better metabolic control and thus reduce the risk of developing chronic complications, including CAN. 3. Specific gene expression in type 1 diabetic patients with and without cardiac autonomic neuropathy. Gastol J, Polus A, Biela M, Razny U, Pawlinski L, Solnica B, Kiec\-Wilk B. Sci Rep. 2020 Mar 27\;10\(1\)\:5554. doi\: 10.1038\/s41598\-020\-62498\-7. \(original work\) 60 patients with T1DM were enrolled in the study, the control group consisted of 20 healthy volunteers. The diagnosis of CAN was documented on the basis of tests using Ewi"]

Number of results: 1